| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | DDR1 ;Phospho Tyr796; Epithelial discoidin domain-containing receptor 1; Epithelial discoidin domain receptor 1; EC 2.7.10.1; CD167 antigen-like family member A; Cell adhesion kinase; Discoidin receptor tyrosine kinase; HGK2; Mammary carcinoma kinase 10; MCK-10; Protein-tyrosine kinase 3A; Protein-tyrosine kinase RTK-6; TRK E; Tyrosine kinase DDR; Tyrosine-protein kinase CAK; CD antigen CD167a |
| Clonality | |
| Concentration | |
| Formulation | |
| Gene ID | |
| Host | |
| Immunogen | Synthesized peptide derived from human DDR1 (Phospho Tyr796) |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Storage | |
| Target |
Product Overview
Primary AntibodyThis antibody targets DDR1 and detects endogenous levels of DDR1 protein. Only detects the phosphorylated form of DDR1.
Validated Applications
| Application | Dilution Guidance |
|---|---|
| Western Blot (WB) | Refer to datasheet for recommended working dilution |
| ELISA | Refer to datasheet for recommended working dilution |
Antibody Specifications
| Target | DDR1 |
|---|---|
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Reactivity | Human, Mouse, Rat |
| Purification | Affinity Purification |
| Molecular Weight | ~100.4 kDa |
| Concentration | 1 mg/ml |
| Immunogen | Synthesized peptide derived from human DDR1 (Phospho Tyr796) |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Storage | -20°C for 1 year |
| Gene ID | Human: 780; Mouse: 12305; Rat: 0 |
| UniProt | Q08345 (Human: Q08345; Mouse: Q03146; Rat: Q63474) |
Scientific Background
Catalytic activity:ATP + a
Alternative Names
DDR1 ;Phospho Tyr796; Epithelial discoidin domain-containing receptor 1; Epithelial discoidin domain receptor 1; EC 2.7.10.1; CD167 antigen-like family member A; Cell adhesion kinase; Discoidin receptor tyrosine kinase; HGK2; Mammary carcinoma kinase 10; MCK-10; Protein-tyrosine kinase 3A; Protein-tyrosine kinase RTK-6; TRK E; Tyrosine kinase DDR; Tyrosine-protein kinase CAK; CD antigen CD167a
Safety & Handling
| Target | DDR1 |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Reactivity | Human, Mouse, Rat |
| Purification | Affinity Purification |
| Molecular Weight | ~100.4 kDa |
| Concentration | 1 mg/ml |
| Immunogen | Synthesized peptide derived from human DDR1 (Phospho Tyr796) |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Storage | -20°C for 1 year |
| Gene ID | Human: 780; Mouse: 12305; Rat: 0 |
| UniProt | Q08345 (Human: Q08345; Mouse: Q03146; Rat: Q63474) |
Optimized working dilutions depend on sample type and detection system. Titration is recommended.
| Application | Dilution Note |
|---|---|
| Western Blot (WB) | Refer to datasheet for recommended working dilution |
| ELISA | Refer to datasheet for recommended working dilution |
Catalytic activity:ATP + a
Alternative Names
DDR1 ;Phospho Tyr796; Epithelial discoidin domain-containing receptor 1; Epithelial discoidin domain receptor 1; EC 2.7.10.1; CD167 antigen-like family member A; Cell adhesion kinase; Discoidin receptor tyrosine kinase; HGK2; Mammary carcinoma kinase 10; MCK-10; Protein-tyrosine kinase 3A; Protein-tyrosine kinase RTK-6; TRK E; Tyrosine kinase DDR; Tyrosine-protein kinase CAK; CD antigen CD167a
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
